Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.47 |
| ▸ | HRH2 | P25021 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ATP4A | P20648 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ATP4B | P51164 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.47 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Impromidine SCHEMBL7175042 | 0.99 | HRH2 (0.47) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| Impromidine SCHEMBL7177531 | 0.99 | HRH2 (0.47) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| Impromidine SCHEMBL636059 | 0.99 | HRH2 (0.47) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| SCHEMBL9865962 | 0.96 | SLC47A1 (0.44) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| Hydrochloric Acid SCHEMBL9866445 | 0.95 | L3MBTL1 (0.45) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| SCHEMBL9866634 | 0.92 | SLC47A1 (0.44) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| Hydrochloric Acid SCHEMBL9867591 | 0.91 | L3MBTL1 (0.45) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| SCHEMBL7179442 | 0.87 | HRH2 (0.34) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| SCHEMBL10859477 | 0.86 | SLC47A1 (0.57) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| SCHEMBL9866816 | 0.86 | SLC47A1 (0.36) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1075 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857600-B2 | GPCR heteromer inhibitors and uses thereof | GPCR THERAPEUTICS, INC. (KR) | 2024-01-02 | — | — | US | claimed |
| US-20230349922-A1 | H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer | UNIVERSITÉ DE STRASBOURG (FR) | 2023-11-02 | — | — | US | claimed |
| EP-4196793-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | Université de Strasbourg (FR) | 2023-06-21 | — | — | EP | claimed |
| WO-2023055751-A1 | MIXED SOLVENT HYDROGEL SYSTEM FOR WOUND HEALING | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-04-06 | — | — | WO | claimed |
| WO-2022034121-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | UNIVERSITÉ DE STRASBOURG (FR) | 2022-02-17 | — | — | WO | claimed |
| EP-3900712-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2021-10-27 | — | — | EP | claimed |
| US-20210146003-A1 | A NOVEL METHOD TO IMPROVE ADHESIVE STRENGTH OF REVERSIBLE POLYMERS AND HYDROGELS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-05-20 | — | — | US | claimed |
| US-20200360478-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS, INC. (KR) | 2020-11-19 | — | — | US | claimed |
| EP-3727371-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2020-10-28 | — | — | EP | claimed |
| US-20200306261-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTION AND/OR TREATMENT OF CANCER | UNIV PENNSYLVANIA (US) | 2020-10-01 | — | — | US | claimed |
| US-5869479-A | ADMINISTERING HISTAMINE H1 RECEPTOR ANTAGONISTS AND HISTAMINE H3 RECEPTOR ANTAGONISTS; NASAL DECONGESTANT WITHOUT THE NERVOUS SYSTEM OR CARDIOVASCULAR SIDE EFFECTS | SCHERING CORPORATION (US) | 1999-02-09 | — | — | US | claimed |
| EP-0655914-A4 | NOVEL COMPOSITIONS. | NAHOUM CESAR ROBERTO DIAS (BR) | 1998-04-22 | — | — | EP | claimed |
| WO-1998006394-A1 | TREATMENT OF UPPER AIRWAY ALLERGIC RESPONSES WITH A COMBINATION OF HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-19 | — | — | WO | claimed |
| WO-1997047292-A1 | USE OF H2-ANTAGONISTS FOR THE MANUFACTURE OF A TOPICAL COMPOSITION FOR THE TREATMENT OF COLDS | THE PROCTER & GAMBLE COMPANY (US) | 1997-12-18 | — | — | WO | claimed |
| EP-0655914-A1 | NOVEL COMPOSITIONS | NAHOUM, Cesar Roberto Dias (BR) | 1995-06-07 | — | — | EP | claimed |
| US-5364616-A | Use of H-2 antagonists for treatment of gingivitis | THE PROCTER & GAMBLE COMPANY (US) | 1994-11-15 | — | — | US | claimed |
| US-5294433-A | Dentistry | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-15 | — | — | US | claimed |
| WO-1994004120-A2 | METHODS OF TREATING SEXUAL DYSFUNCTION IN ANIMALS WITH AND H AGONIST | NAHOUM CESAR ROBERTO DIAS (BR) | 1994-03-03 | — | — | WO | claimed |
| WO-1993020815-A1 | USE OF H-2 ANTAGONISTS FOR TREATMENT OF GINGIVITIS | THE PROCTER & GAMBLE COMPANY (US) | 1993-10-28 | — | — | WO | claimed |
| US-4474876-A | Flow cytometric analysis of histamine receptors | TRUSTEES OF BOSTON UNIVERSITY (US) | 1984-10-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306261-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTION AND/OR TREATMENT OF CANCER | GPER1, GPR3, GPR4 | SLC47A1 2016/4885HRH2 876/4885SMN1; SMN2 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.